^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
8R-70CAR T
i
Other names: 8R-70CAR T, Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells, Phase IL-8 receptor modified Patient-derived activated CD70 CAR T
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
University of Florida
Drug class:
CD70-targeted CAR-T immunotherapy
Related drugs:
5ms
CD70 CXCR2-Modified CAR T-Cells Against Acute Myeloid Leukemia (TCT-ASTCT-CIBMTR 2024)
8R-70CAR T cells are able to specifically recognize and kill CD70+ AML cells, and cytotoxicity may be augmented by enhancing CD70 expression with azacytidine pre-treatment. A LLS tumoroid model can aid in 3D visualization of 8R-70CAR T cells interactions AML cells. These findings combined with safety data obtained from our ongoing phase I clinical trial for adults with glioblastoma (NCT05353530) will support expansion of our existing IND to treat patients with AML using our novel 8R-70CAR.
CAR T-Cell Therapy
|
IFNG (Interferon, gamma) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • CD70 (CD70 Molecule) • CXCR2 (Chemokine (C-X-C motif) receptor 2)
|
MLL rearrangement • CD70 expression • IFNG expression • CXCL8 expression • CXCL8 overexpression
|
azacitidine • 8R-70CAR T
10ms
Phase I Study of IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ and MGMT-unmethylated Adult Glioblastoma (IMPACT) (clinicaltrials.gov)
P1, N=18, Recruiting, University of Florida | Not yet recruiting --> Recruiting | Trial completion date: Dec 2041 --> Dec 2042 | Trial primary completion date: Dec 2026 --> Dec 2027
Enrollment open • Trial completion date • Trial primary completion date • CAR T-Cell Therapy
|
MGMT (6-O-methylguanine-DNA methyltransferase) • CD70 (CD70 Molecule)
|
8R-70CAR T
1year
Phase I Study of IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ and MGMT-unmethylated Adult Glioblastoma (IMPACT) (clinicaltrials.gov)
P1, N=18, Not yet recruiting, University of Florida | Trial completion date: Dec 2040 --> Dec 2041 | Trial primary completion date: Dec 2025 --> Dec 2026
Trial completion date • Trial primary completion date • CAR T-Cell Therapy
|
MGMT (6-O-methylguanine-DNA methyltransferase) • CD70 (CD70 Molecule)
|
8R-70CAR T
almost2years
Phase I Study of IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ and MGMT-unmethylated Adult Glioblastoma (IMPACT) (clinicaltrials.gov)
P1, N=18, Not yet recruiting, University of Florida | Initiation date: Jun 2022 --> Oct 2022
Trial initiation date • CAR T-Cell Therapy
|
MGMT (6-O-methylguanine-DNA methyltransferase) • CD70 (CD70 Molecule)
|
8R-70CAR T
2years
IMPACT: Phase I Study of CD70 CAR T Cell Therapy in CD70+ and MGMT-unmethylated Adult GBM (clinicaltrials.gov)
P1, N=18, Not yet recruiting, University of Florida
New P1 trial • CAR T-Cell Therapy
|
MGMT (6-O-methylguanine-DNA methyltransferase) • CD70 (CD70 Molecule)
|
CD70 expression
|
8R-70CAR T
Share via
